Publications by authors named "Meghna Samant"

Claim this Profile
R
Response- and Progression-Based End Points in Trial and Observational Cohorts of Patients With NSCLC.
Yichen Lu, Spencer S Langerman, Emily McCain, Kelly Magee, Sophia L Maund, Meghna Samant

JAMA Netw Open· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic approach towards missing lab data in electronic health records: A case study in non-small cell lung cancer and multiple myeloma.
Arjun Sondhi, Janick Weberpals, Prakirthi Yerram, Chengsheng Jiang, Michael Taylor, Meghna Samant

CPT Pharmacometrics Syst Pharmacol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for pooling real-world data as a comparator cohort to a single arm trial: a simulation study on assessment of heterogeneity.
Daniel Backenroth, Trevor Royce, Jose Pinheiro, Meghna Samant, Olivier Humblet

BMC Med Res Methodol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study.
Sanhita Sengupta, Ives Ntambwe, Katherine Tan, Qixing Liang, David Paulucci, Meghna Samant

Clin Pharmacol Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations.
W Katherine Tan, Brian D Segal, Melissa D Curtis, Shrujal S Baxi, William B Capra, Meghna Samant

Contemp Clin Trials Commun· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concordance of Clinician-Documented and Imaging Response in Patients With Stage IV Non-Small Cell Lung Cancer Treated With First-Line Therapy.
Xinran Ma, Lawrence Bellomo, Ian Hooley, Tori Williams, Meghna Samant

JAMA Netw Open· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC.
Xinran Ma, Lawrence Bellomo, Kelly Magee, Caroline S Bennette, Olga Tymejczyk, Meghna Samant

Adv Ther· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small But Mighty: The Use of Real-World Evidence to Inform Precision Medicine.
Rebecca A Miksad, Meghna K Samant, Somnath Sarkar, Amy P Abernethy

Clin Pharmacol Ther· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Chunze Li, Bei Wang, Shang-Chiung Chen, Russell Wada, Dan Lu, Meghna Samant

Cancer Chemother Pharmacol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
José Baselga, Gail D Lewis Phillips, Sunil Verma, Jungsil Ro, Jens Huober, Meghna K Samant

Clin Cancer Res· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
Véronique Diéras, Nadia Harbeck, G Thomas Budd, Joel K Greenson, Alice E Guardino, Meghna Samant

J Clin Oncol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
Dan Lu, Sandhya Girish, Yuying Gao, Bei Wang, Joo-Hee Yi, Meghna Samant

Cancer Chemother Pharmacol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
James J Vredenburgh, Timothy Cloughesy, Meghna Samant, Michael Prados, Patrick Y Wen

Oncologist· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.
Michael Prados, Timothy Cloughesy, Meghna Samant, Liang Fang, Patrick Y Wen

Neuro Oncol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Mark A Socinski, Frank A Scappaticci, Meghna Samant, Margaret M Kolb, Mark F Kozloff

J Thorac Oncol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
Alan B Sandler, Joan H Schiller, Robert Gray, Isaiah Dimery, Julie Brahmer, Meghna Samant

J Clin Oncol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis